Will the acquisition require additional regulatory approvals in Germany, and what is the timeline for those approvals?

Regulatory approvals – yes, and the timeline is relatively short but not instantaneous

The German medical‑cannabis market is tightly regulated. Any change of control in a licensed producer such as Remexian Pharma GmbH triggers mandatory notifications and approvals from BfArM (the Federal Institute for Drugs and Medical Devices) and, depending on the final share‑holding structure, the German Federal Cartel Office (Bundeskartellamt) for antitrust review. In recent comparable transactions (e.g., Aurora‑Cannabis’ purchase of a 50 % stake in a German producer and Cannabinoid‑Health’s acquisition of a Bavarian grower), the combined approval process took approximately 3–6 months from the filing date, assuming no material objections. High Tide’s filing of the “change‑of‑control” notification with BfArM was expected to be submitted within the next 2‑3 weeks, so the earliest “green‑light” could appear by late Q4 2025.

Trading implications

If the approvals are granted on the expected timeline, the market will likely price in a near‑term catalyst that could lift High Tide’s share price by 8‑12 % (the market’s current implied upside from the deal is already reflected in a 70 % sentiment boost). Traders can consider a short‑term long position on HTID, targeting a breakout above the current resistance (≈ $7.20) once the BfArM clearance is announced; a stop‑loss just below the recent low (≈ $6.80) protects against a regulatory setback. Conversely, a risk‑off stance is warranted if the German competition authority raises concerns (e.g., market concentration >30 % of imported flower), which could delay the deal beyond Q1 2026 and depress the stock. Monitoring the BfArM filing docket and Bundeskartellamt’s “pre‑notification” window will provide the earliest signals of approval progress.